Guide · 6 min · 2026-07-23
On-prem vs cloud for Indian pharma data residency
How pharmaceutical plants in India can think about on-premises and private-cloud deployment for GxP software—without forced public SaaS.
Why residency comes up
Quality and manufacturing records are sensitive. Leadership often wants clear answers about where data lives, who can access it, and what happens if a public network path is unavailable. Those questions are practical—not merely theoretical.
On-prem and private cloud are both valid
Running inside your plant network or your private cloud can satisfy residency policies while still delivering modern software. The decision should follow your risk assessment and IT capacity—not a vendor’s preferred hosting story alone.
Questions to ask every vendor
Can the full suite run without mandatory phone-home for day-to-day work? How do licenses activate offline? Where does AI inference run if you use assistants? Who holds backups and keys?
Export markets still matter
Domestic residency choices should not prevent credible electronic records themes for overseas customers and regulators. Look for platforms designed for both Indian plant life and export conversations.
Novaqis posture
Novaqis is built to deploy on your infrastructure. Nova AI can run inside your perimeter. We do not require public SaaS as the only path. Contact us to map a deployment that fits your policies.
Ready to see Novaqis on your terms?
We prefer live walkthroughs over generic slides. Ask for a demo or a tailored quote—no published list prices.